Discrepancies in Beta-Lactam Antibiotics Cross-Reactivity: Implications for Clinical Practice

Area of Science:

• Clinical Allergy and Immunology
• Infectious Diseases
• Pharmacology

Background:

• Beta-lactam antibiotic (BA) allergy labels can lead to avoidance of crucial first-line treatments, impacting patient outcomes and antimicrobial resistance.
• Existing studies on BA cross-reactivity offer conflicting recommendations for safe alternative antibiotics.
• Discrepancies in BA cross-allergy data hinder optimal clinical decision-making.

Purpose of the Study:

• To identify discrepancies in beta-lactam antibiotic (BA) cross-allergy recommendations across different studies.
• To pinpoint research gaps concerning safe BA alternatives for patients with suspected BA allergies.

Main Methods:

• A head-to-head comparison of cross-allergy tables and errata from four key studies (Romano et al., Trubiano et al., Zagursky et al., SWAB-guideline).
• Evaluation of 51 antibiotics and their potential cross-reactivity recommendations.

Main Results:

• Significant disharmony was found in 36% of cases across the evaluated studies.
• In 69% of discordant cases, the advice on alternative BAs differed, leading to potentially unsafe recommendations.
• Data gaps existed for 356 specific BA alternatives, and only one author provided advice in 1104 situations.

Conclusions:

• A substantial 36% disharmony rate among studies necessitates synchronized cross-reactivity tables.
• Clinically relevant, differing advice in 69% of cases underscores the urgent need for standardized guidelines.
• Addressing identified research gaps is crucial for improving the safety and efficacy of antibiotic selection in BA-allergic patients.